ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • 2026 ACR/ARP PRSYM
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "Systemic sclerosis"

  • Abstract Number: 810 • 2018 ACR/ARHP Annual Meeting

    Sexual Dysfunction in Women with Systemic Sclerosis

    Marina Soledad Dalpiaz1, Juan Argüello2, Maria Florencia Rodriguez3, Marta Mamani4, Anastasia Secco5, Natalia Tamborenea2, Eduardo Kerzberg6, Sandra Fabiana Montoya6, Carolina Aimo6, Fernando Manuel Villalobos6, Eliana Rebeca Serrano7, Maria Elena Crespo Espindola8 and Ana Lía Gervilla Galan9, 1Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, 2Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 3Reumatologia, Hospital Bernardino Rivadavia, Ciudad Autónoma de Buenos Aires, Argentina, 4Rheumatology Department, Hospital Bernardino Rivadavia, Buenos Aires, Argentina, 5Rheumatology Section, Hospital Bernardino Rivadavia, CABA, Argentina, 6Hospital General de Agudos José María Ramos Mejía, BUENOS AIRES, Argentina, 7Rheumatology Section, Hospital General de Agudos Dr. Enrique Tornú, Buenos Aires, Argentina, 8Reumatologia, Hospital Señor del Milagro, Salta, Argentina, 9Hospital San Roque, San Salvador de Jujuy, Argentina

    Background/Purpose: Impaired sexual function is common among women with chronic illnesses, including Systemic Sclerosis (SSc). Studies of sexual functioning among women with SSc have concluded…
  • Abstract Number: 898 • 2018 ACR/ARHP Annual Meeting

    Efficacy and Safety of Tocilizumab for the Treatment of Systemic Sclerosis: Results from a Phase 3 Randomized Controlled  Trial

    Dinesh Khanna1, Celia J. F. Lin2, Masataka Kuwana3, Yannick Allanore4, Anastas Batalov5, Irena Butrimiene6, Patricia Carreira7, Marco Matucci Cerinic8, Oliver Distler9, Dusanka Martinović Kaliterna10, Carina Mihai11, Mette Mogensen12, Marzena Olesinska13, Janet E. Pope14, Gabriela Riemekasten15, Tatiana S. Rodriguez-Reyna16, Maria José Santos17, Jacob van Laar18, Helen Spotswood19, Jeffrey Siegel2, Angelika Jahreis2, Daniel E. Furst20 and Christopher P. Denton21, 1University of Michigan, Ann Arbor, MI, 2Genentech, Inc., South San Francisco, CA, 3Nippon Medical School, Tokyo, Japan, 4Cochin Hospital, Paris Descartes University, Paris, France, Paris, France, 5Medical University of Plovdiv, Plovdiv, Bulgaria, 6Rheumatology Clinic, Medical Faculty, Vilnius University, Vilnius, Lithuania, 7Servicio de Reumatología, Hospital Universitario, Madrid, Spain, 8University of Florence, Florence, Italy, 9Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 10University of Split, Split, Croatia, 11Cantacuzino Hospital, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania, 12Department of Dermatology, Bispebjerg Hospital, Copenhagen, Denmark, 13National Institute of Geriatrics, Rheumatology and Rehabilitation,, Warsaw, Poland, 14Department of Medicine, University of Western Ontario, London, ON, Canada, 15Rheumatology, University Hospital Schleswig-Holstein - Campus Lübeck, Lübeck, Germany, 16Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, 17Serviço de Reumatologia do Hospital Garcia de Orta, Almada, Portugal, Almada, Portugal, 18University Medical Center Utrecht, Utrecht, Netherlands, 19Roche Products Ltd., Welwyn Garden City, United Kingdom, 20University of California Los Angeles, Los Angeles, CA, 21University College London, London, United Kingdom

    Background/Purpose: The anti–interleukin-6 (IL-6) receptor-alpha antibody tocilizumab (TCZ) demonstrated numeric improvement in skin thickening (modified Rodnan skin score [mRSS]) and clinically meaningful lung function preservation…
  • Abstract Number: 1212 • 2018 ACR/ARHP Annual Meeting

    Superiority of Musculoskeletal Ultrasound (MSUS) over Clinical Examination Regarding Detection of Arthritis in Patients with Systemic Sclerosis

    Daria Feldmann1, Reinhard Voll2, Florian Kollert3 and Stephanie Finzel1, 1Department of Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 2Clinic for Rheumatology and Clinical Immunology, University Medical Center Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany, 3Department of Rheumatology, Immunology, and Allergology, Inselspital, University Hospital Bern, Bern, Switzerland

    Background/Purpose: Arthralgia is frequent in patients with systemic sclerosis (SSc). However, correct clinical assessment of arthritis remains a challenge especially in patients with severe soft…
  • Abstract Number: 1726 • 2018 ACR/ARHP Annual Meeting

    Sexual Dysfunction in Systemic Sclerosis Female Patients

    Barbora Hermankova1,2, Maja Spiritovic1,2, Hana Smucrova2, Sabina Oreska2,3, Hana Storkanova2,3, Karel Pavelka3,4, Jiri Vencovsky2,5, Ladislav Šenolt2,3, Radim Becvar2,3 and Michal Tomcik2,3, 1Department of Physiotherapy, Faculty of Physical Education and Sports, Charles University, Prague, Czech Republic, Prague, Czech Republic, 2Institute of Rheumatology, Prague, Czech Republic, Prague, Czech Republic, 3Department of Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 4Institute of Rheumatology, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic, 5Department Rheumatology, First Faculty of Medicine, Charles University, Prague, Czech Republic, Prague, Czech Republic

    Background/Purpose: Systemic sclerosis (SSc) is a chronic autoimmune disease leading to various physical and psychological impairments including sexual dysfunction. The aim of this study was…
  • Abstract Number: 1738 • 2018 ACR/ARHP Annual Meeting

    Detect Outperforms Echocardiography Based Screening Guidelines for Early Detection of Systemic Sclerosis Associated Pulmonary Arterial Hypertension

    Amber Young1, Victor M. Moles2,3, Vivek Nagaraja1, Dharshan Vummidi4, Scott H. Visovatti3, Vallerie McLaughlin3 and Dinesh Khanna1, 1Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI, 2Hospital Jose Maria Cullen, Santa Fe, Argentina, 3Division of Cardiology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, 4Department of Radiology, University of Michigan, Ann Arbor, MI

    Background/Purpose: Pulmonary arterial hypertension (PAH) is a leading cause of mortality in patients with systemic sclerosis (SSc). Active screening can detect SSc-PAH earlier and may…
  • Abstract Number: 1900 • 2018 ACR/ARHP Annual Meeting

    FGFR3/ FGF9 Regulates the Activity of Profibrotic Cytokine and Growth Factor Pathways to Drive Fibroblast Activation and Tissue Fibrosis in Systemic Sclerosis

    Debomita Chakraborty1, Lena Summa2, Thuong Trinh-Minh3, Chih-Wei Chen3, Alina Soare2, Andreas Ramming4, Oliver Distler5, Georg Schett2 and Jörg Distler3, 1Department of Internal Medicine 3- Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 2Department of Internal Medicine 3-Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 3Department of Internal Medicine 3 – Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 4Department of Internal Medicine 3 and Institute for Clinical Immunology, Friedrich-Alexander-University Erlangen-Nürnberg (FAU) and University Hospital Erlangen, Erlangen, Germany, 5Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland

    Background/Purpose: Fibroblast growth factor receptor3 (FGFR3) is a member of the family of 4 different receptors (FGFR1-4) with more than 23 identified ligands FGF1-23. Each…
  • Abstract Number: 2688 • 2018 ACR/ARHP Annual Meeting

    Increased Serum Uric Acid Levels Are Associated with a Higher Risk of Digital Ulcers in Patients with Systemic Sclerosis

    Han-Na Lee1, Seung-Geun Lee1, Eunsung Kim1, JungHee Koh1, Yun-Kyung Kim2, Ho-Jae Kim2 and Geun-Tae Kim3, 1Division of Rheumatology, Department of Internal Medicine, Pusan National University School of Medicine, Pusan National University Hospital, Busan, Korea, Republic of (South), 2Division of Rheumatology, Department of Internal Medicine, Kosin University College of Medicine, Busan, Korea, Republic of (South), 3Kosin University College of Medicine, Busan, Korea, Republic of (South)

    Background/Purpose: Endothelial cell dysfunction and/or injury are considered critical early events in the pathogenesis of vasculopathy in patients with systemic sclerosis (SSc). Hyperuricemia is known…
  • Abstract Number: 2695 • 2018 ACR/ARHP Annual Meeting

    Progressive Skin Fibrosis, Internal Organ Involvement and All-Cause Mortality in an Early Diffuse Cutaneous Systemic Sclerosis United States Multicenter Registry

    Kate Homer1, Benjamin Brennan2, Shervin Assassi3, Elana J. Bernstein4, Flavia V. Castelino5, Robyn T. Domsic6, Jessica K. Gordon7, Faye N. Hant8, Monique Hinchcliff9, Ami A. Shah10, Victoria Shanmugam11, Virginia D. Steen12, Veronica J. Berrocal13, Melanie Hemmrich14, Tracy M. Frech15 and Dinesh Khanna16, 1Department of Internal Medicine, Rheumatology Division, Scleroderma Program, University of Michigan, Ann Arbor, MI, 2School of Public Health, University of Michigan, Ann Arbor, MI, 3University of Texas McGovern Medical School, Houston, TX, 4Rheumatology, Columbia University, New York, NY, 5Rheumatology, Harvard Medical School, Boston, MA, 6Medicine - Rheumatology, University of Pittsburgh, Pittsburgh, PA, 7Rheumatology, Hospital for Special Surgery, New York, NY, 8Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC, 9Rheumatology, Northwestern University, Chicago, IL, 10Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, 11Rheumatology, The George Washington University, Washington, DC, 12Rheumatology, MedStar Georgetown University Hospital, Washington, DC, 13Div of Rheumatology, University of Michigan, Ann Arbor, MI, 14Bayer AG, Wuppertal, Germany, 15Division of Rheumatology, University of Utah, Salt Lake City, UT, 16Division of Rheumatology, Department of Internal Medicine, University of Michigan Scleroderma Program, University of Michigan, Ann Arbor, MI

    Background/Purpose: Early diffuse cutaneous systemic sclerosis (dcSSc) carries a high morbidity and mortality, predominantly due to internal organ involvement. The purpose of this study was…
  • Abstract Number: 1678 • 2017 ACR/ARHP Annual Meeting

    Pathogenic Mechanisms of Esophageal Peristaltic Dysfunction By High Resolution Manometry in Patients with Systemic Sclerosis

    Hyun-Sook Kim1, Yunseok Kim2, Jung Ran Choi3 and Joon Seong Lee2, 1Soonchenhyang university school of medicine, Seoul, Korea, Republic of (South), 2Internal medicine, Soonchunhyang university Seoul hospital, Seoul, Korea, Republic of (South), 3Department of Internal Medicine, Pohang St. Mary Hospital, Pohang, Korea, Republic of (South)

    Background/Purpose: Pathogenic mechanisms of esophageal involvement in systemic sclerosis (SSc) were suggested as neural dysfunction due to impairment of microcirculation to intramural neuron in early…
  • Abstract Number: 1691 • 2017 ACR/ARHP Annual Meeting

    Risk of Development of Definite Disease in Patients with Early Systemic Sclerosis

    Cintia Zumstein Camargo, Maria Izabel Arismendi and Cristiane Kayser, Rheumatology Division, Universidade Federal de São Paulo, São Paulo, Brazil

    Background/Purpose: The diagnosis of systemic sclerosis (SSc) in the early stages of the disease is frequently a challenge. In 2001, LeRoy and Medsger proposed criteria…
  • Abstract Number: 1704 • 2017 ACR/ARHP Annual Meeting

    Non-Randomized Controlled Trial to Evaluate the Effect of Extracorporeal Shock Wave Therapy on Digital Ulcers in Systemic Sclerosis

    Tomonori Ishii1, Yasushi Kawaguchi2, osamu ishikawa3, naruhiko takasaawa4, takao kodera5, hidekata yasuoka6, yuichi takahashi7, osamu takai8, Izaya Nakaya9, Hiroshi Fujii10, Yukiko Kamogawa10, Yuko Shirota10, Tsuyoshi Shirai10, Yoko Fujita11, shinichiro saito12, Hiroaki Shimokawa13 and Hideo Harigae10, 1Clinical Research, Innovation and Education Center, Tohoku University Hospital, Sendai, Japan, 2Institute of Rheumatology, Tokyo Women's Medical University, Tokyo, Japan, 3Department of Dermatology, Gunma University Graduate School of Medicine, gunma, Japan, 4Department of Internal Medicine, Tohoku Medical and Pharmaceutical University Wakabayashi Hospital, Sendai, Japan, 5Division of Hematology and Rheumatology, Tohoku Medical and Pharmaceutical University, Sendai, Japan, 6Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, tokyo, Japan, 7Yu Family Clinic, Sendai, Japan, 8Osaki Citizen Hospital, Sendai, Japan, 9Department of Nephrology and Rheumatology, Iwate Prefectural Central Hospital, Morioka, Japan, 10Department of Hematology and Rheumatology, Tohoku University Graduate School of Medicine, Sendai, Japan, 11Department of Hematolgy and Rheumatolgy, Tohoku University Graduate School of Medicine, Sendai, Japan, 12IMS Meirikai Sendai General Hospital, Sendai, Japan, 13Department of Cardiovascular medicine, Tohoku University Graduate School of Medicine, Sendai, Japan

    Background/Purpose: Patients with systemic sclerosis (SSc) often display Raynaud’s phenomenon, which causes digital skin ulcers. Since these ulcers are not associated with autoimmune factors, conventional…
  • Abstract Number: 1720 • 2017 ACR/ARHP Annual Meeting

    TGF-ß-Induced Tissue Fibrosis in TBRIcaCol1Cre Transgenic Mice Is Abrogated By the Second Generation Tyrosine Kinase Inhibitor SKI-606 (Bosutinib)

    Peter J. Wermuth and Sergio A. Jimenez, Jefferson Institute of Molecular Medicine, Division of Connective Tissue Diseases and Scleroderma Center, Thomas Jefferson University, Philadelphia, PA

    Background/Purpose: Bosutinib (SKI-606), a second-generation tyrosine kinase inhibitor that blocks the activity of the BCR-ABL kinase responsible for Philadelphia chromosome positive chronic myeloid leukemias, also…
  • Abstract Number: 2049 • 2017 ACR/ARHP Annual Meeting

    Factor Structure and Convergent Validity of the Derriford Appearance Scale-24 Using Standard Scoring Versus Treating “Not Applicable” Responses As Missing Data: A Scleroderma Patient-Centered Intervention Network Cohort Study

    Erin L. Merz1, Linda Kwakkenbos2,3,4, Marie-Eve Carrier2, Shadi Gholizadeh5, Sarah D. Mills6, Rina S. Fox7, Lisa Jewett2,8, Heidi Williamson9, Diana Harcourt9, Shervin Assassi10, Daniel E. Furst11, Karen Gottesman12, Maureen D Mayes13, Tim Moss9, Brett D. Thombs2,3 and Vanessa L. Malcarne6,14, 1Department of Psychology, California State University, Dominguez Hills, Carson, CA, 2McGill University, Montreal, QC, Canada, 3Lady Davis Institute for Medical Research, Jewish General Hospital, Montreal, QC, Canada, 4Radboud University, Nijmegen, Netherlands, 5Psychoogy, SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 6SDSU/UC San Diego Joint Doctoral Program in Clinical Psychology, San Diego, CA, 7Northwestern University Feinberg School of Medicine, Chicago, IL, 8Jewish General Hospital, Montreal, QC, Canada, 9University of the West of England, Bristol, United Kingdom, 10University of Texas McGovern Medical School, Houston, TX, 11Department of Internal Medicine and Rheumarology, University of California Los Angeles, David Geffen School of Medicine, Division of Rheumatology; University of Washington, Seattlr, Washington; University of Florence, Florence, Italy, Los Angeles, CA, 12Scleroderma Foundation, Los Angeles, CA, 13Department of Internal Medicine - Rheumatology, University of Texas-McGovern Medical School, Houston, TX, 14Psychology, San Diego State University, San Diego, CA

    Background/Purpose: Valid measures of appearance concern are needed in systemic sclerosis, a rare, disfiguring rheumatologic disease. The Derriford Appearance Scale-24 (DAS-24) is a self-report measure…
  • Abstract Number: 2670 • 2017 ACR/ARHP Annual Meeting

    Trigeminal Neuralgia in Systemic Sclerosis

    Nancy Maltez1, Marie Hudson2, Yves Troyanov3, May Choi4, Mianbo Wang5, Marvin J. Fritzler6, Murray Baron7 and Doug Smith8, 1Rheumatology, The Ottawa Hospital, Ottawa, ON, Canada, 2Division of Rheumatology, Jewish General Hospital, Lady David Institute for Medical Research, Montreal, QC, Canada, 3Rheumatology, Hôpital du Sacré-Coeur de Montréal, Montréal, QC, Canada, 4University of Calgary, Calgary, AB, Canada, 5Lady Davis Institute for Medical Research, Montreal, QC, Canada, 6Medicine, University of Calgary, Calgary, AB, Canada, 7Rheumatology, McGill University, Jewish General Hospital, Montreal, QC, Canada, 8Division of Rheumatology, Department of Medicine, The Ottawa Hospital - University of Ottawa, Ottawa, ON, Canada

    Background/Purpose: Trigeminal neuralgia (TN) is characterized by pain and spasms affecting one or more divisions of the fifth cranial nerve. Of note, TN is one…
  • Abstract Number: 2685 • 2017 ACR/ARHP Annual Meeting

    Sensitivity and Specificity of YKL-40 for the Presence of Pulmonary Arterial Hypertension in Systemic Sclerosis

    Tetsuya Furukawa1, Kiyoshi Matsui2, Masayasu Kitano2, Yuichi Yokoyama3, Naoto Azuma2 and Hajime Sano2, 1Division ofRheumatology Department of internal medicine, Hyogo College of Medicine, Nishinomiya, Japan, 2Division of Rheumatology, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan, 3Division of Rheumatology, Department of internal medicine, Hyogo College of Medicine, Nishinomiya, Japan

    Background/Purpose: Systemic sclerosis (SSc) is an intractable connective tissue disease that causes fibrosis of the skin and organs. The prognosis of this disease is affected…
  • « Previous Page
  • 1
  • …
  • 48
  • 49
  • 50
  • 51
  • 52
  • …
  • 56
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to PRYSM are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 6:00 PM CT on March 18. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology